Insider Selling: Omeros (NASDAQ:OMER) Director Sells $92,650.00 in Stock

Posted by Francis Steltz on Aug 31st, 2026

Omeros Corporation (NASDAQ:OMER – Get Free Report) Director Arnold Hanish sold 5,000 shares of the stock in a transaction on Wednesday, August 26th. The stock was sold at an average price of $18.53, for a total transaction of $92,650.00. Following the sale, the director directly owned 5,000 shares in the company, valued at $92,650. This trade represents a 50.00% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Omeros Price Performance

OMER stock opened at $18.61 on Monday. The firm has a market cap of $1.35 billion, a P/E ratio of 14.54 and a beta of 2.54. The company’s 50-day simple moving average is $12.64 and its 200-day simple moving average is $12.03. Omeros Corporation has a 52-week low of $3.94 and a 52-week high of $19.65.

Omeros (NASDAQ:OMER – Get Free Report) last issued its quarterly earnings data on Thursday, August 13th. The biopharmaceutical company reported $0.02 EPS for the quarter, beating the consensus estimate of ($0.27) by $0.29. The business had revenue of $28.53 million during the quarter, compared to analyst estimates of $12.69 million. On average, analysts anticipate that Omeros Corporation will post -0.37 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on OMER. Weiss Ratings upgraded Omeros from a “sell (d+)” rating to a “hold (c-)” rating in a report on Wednesday, August 5th. HC Wainwright restated a “buy” rating on shares of Omeros in a report on Monday, July 27th. Zacks Research cut shares of Omeros from a “strong-buy” rating to a “hold” rating in a research report on Monday, July 13th. Finally, Wall Street Zen upgraded shares of Omeros from a “hold” rating to a “buy” rating in a report on Saturday, August 15th. One analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and three have issued a Hold rating to the company. According to MarketBeat, Omeros has an average rating of “Moderate Buy” and an average target price of $38.00.

Read Our Latest Report on Omeros

Institutional Trading of Omeros

Several hedge funds have recently made changes to their positions in the business. UBS Group AG increased its stake in Omeros by 213.5% during the 4th quarter. UBS Group AG now owns 2,222,982 shares of the biopharmaceutical company’s stock worth $38,180,000 after buying an additional 1,513,893 shares during the period. Dimensional Fund Advisors LP grew its stake in shares of Omeros by 85.2% in the first quarter. Dimensional Fund Advisors LP now owns 179,594 shares of the biopharmaceutical company’s stock worth $1,897,000 after acquiring an additional 82,646 shares in the last quarter. Ancora Advisors LLC acquired a new position in shares of Omeros in the second quarter worth $1,605,000. Corient Private Wealth LLC increased its position in shares of Omeros by 13.0% during the fourth quarter. Corient Private Wealth LLC now owns 688,025 shares of the biopharmaceutical company’s stock worth $11,817,000 after acquiring an additional 79,263 shares during the period. Finally, Quantinno Capital Management LP raised its stake in shares of Omeros by 145.4% in the first quarter. Quantinno Capital Management LP now owns 61,541 shares of the biopharmaceutical company’s stock valued at $650,000 after acquiring an additional 36,467 shares in the last quarter. Institutional investors and hedge funds own 48.79% of the company’s stock.

About Omeros

(Get Free Report)

Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company’s research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros’s portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.

Omeros’s first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.